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DDX3X is a multifunctional RNA helicase with documented roles in different
cancer types. Here, we demonstrate that DDX3X plays an oncogenic role in
breast cancer cells by modulating the cell cycle. Depletion of DDX3X in
MCF7 cells slows cell proliferation by inducing a G1 phase arrest. Notably,
DDX3X inhibits expression of Kruppel-like factor 4 (KLF4), a transcription
factor and cell cycle repressor. Moreover, DDX3X directly interacts with
KLF4 mRNA and regulates its splicing. We show that DDX3X-mediated
repression of KLF4 promotes expression of S-phase inducing genes in MCF7
breast cancer cells. These findings provide evidence for a novel function of
DDX3X in regulating expression and downstream functions of KLF4, a
master negative regulator of the cell cycle.
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DEAD-BOX (DDX) RNA helicases belong to a large
family of proteins characterized by the presence of a
DEAD/H (Asp-Glu-Ala-Asp/His) motif. Their main
function is to unwind double stranded RNA to pro-
mote downstream molecular events. Despite a very
high structural conservation of their functional helicase
core, individual members of this protein family per-
form very different functions in RNA metabolism, all
of which require multistep association/dissociation of
large ribonucleoprotein complexes and modulation of
RNA structures [1–3].
DEAD-box proteins function as transcriptional reg-
ulators [4] and interact with spliceosome components
[5,6]. They also mediate ribosome biogenesis [7], RNA
export [8], translation initiation and termination [9–11]
and mRNA degradation [12]. Depending on the cellu-
lar and signalling context, the outcome of DDXs’
activity on their target RNAs can either promote gene
expression or repress it.
Given the widespread activity of DEAD-box heli-
cases in regulating gene expression at different levels,
and the numerous studies reporting their involvement
in cellular growth [1], it is not surprising that alter-
ations in their expression or function can potentially
affect normal cellular homeostasis and contribute to
cancer development and progression [13].
Ded1/DDX3 is one of the most widely studied and
evolutionary conserved DEAD-box RNA helicase sub-
families [14,15]. The human genome encodes two
DDX3 homologues located on the sex chromosomes:
DDX3X and DDX3Y [16–18]. DDX3X is ubiquitously
expressed in all tissues [15,18] (https://www.proteinatla
s.org/ENSG00000215301-DDX3X/tissue) and func-
tional studies have implicated this protein in multiple
processes of RNA regulation. Although DDX3X is
predominantly localized within the cytoplasm, which is
consistent with a translational regulation function [14],
evidence supporting nuclear functions of the helicase
(including roles in transcription, pre-mRNA splicing,
and mRNA export) also exists [14,16].
The role of DDX3X in cancer biology has been
studied in numerous different cancer models and
Abbreviations
ChIP, chromatin immunoprecipitation; CLIP, cross-linking immunoprecipitation; KLF4, Kruppel-like factor 4; PI, propidium iodide.
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altered expression of DDX3X or mutations in the
DDX3X locus, have been correlated to cancer in differ-
ent tissues [19–24]. In in vitro studies, the oncogenic
activity of DDX3X has been mainly related to the
control of cell growth, cell cycle progression and cell
motility, but the mechanisms and the pathways
through which DDX3X regulates these biological pro-
cesses have only been partially uncovered.
The role of DDX3X in breast cancer has been sug-
gested by both in vitro and clinical studies. In vitro,
over-expression of DDX3X in nontumourigenic breast
epithelial cells (MCF10A) results in increased invasive
cell properties [25]. Conversely, knockdown of
DDX3X decreases cell proliferation and clonogenic
cell capacity in breast cancer cell lines (MCF-7 and
MDA-MB-231) [26,27]. Importantly, studies in
patients’ samples highlighted the oncogenic potential
of DDX3X overexpression by showing it correlates
with distant breast cancer metastases formation and a
worse overall patient survival [28]. However, although
these findings suggest a role for DDX3X in breast can-
cer, detailed investigations into its biological and
molecular functions have not been performed.
Here, we report a mechanism through which
DDX3X regulates the cell cycle of breast cancer MCF7
cells. We find that DDX3X functions to repress expres-
sion of Kruppel-like factor 4 (KLF4), a zinc finger-con-
taining transcription factor and cell cycle repressor
associated with growth arrest. Knockdown of DDX3X
in MCF7 breast cancer cells induces expression of
KLF4, alters KLF4 mRNA exon usage and down-regu-
lates cell cycle factors genes, CCNA2 and CDK2, lead-
ing to reduced cell growth. Thus, DDX3X promotes
MCF7 cell proliferation, at least in part, by inhibiting
expression of the key negative cell cycle regulator,
KLF4. These findings are consistent with DDX3X
playing an oncogenic role in MCF7 cells.
Materials and methods
Cell lines and mammalian tissue culture
Human transformed breast epithelial cancer cell line
MCF7 and human breast epithelial metastatic cell line
MDA-MB-231 were cultured in Dulbecco’s modified
eagle medium (DMEM) (Invitrogen, Carlsbad, CA,
USA) both supplemented with 10% (v/v) FBS and 1%
(w/v) penicillin/streptomycin/glutamine. Human immor-
talized nontumourigenic breast epithelial MCF10A cells
were cultured in DMEM/F12 (Invitrogen) supplemented
with 5% (v/v) horse serum, 20 ngmL1 EGF,
0.5 mgmL1 hydrocortisone, 100 ngmL1 cholera toxin,
10 lgmL1 insulin and 1% (w/v) penicillin/streptomycin.
Cell growth assays
For cell proliferation assay, cells were seeded at 3 9 104 in
2 mL of complete medium in three biological replicates,
24 h after transfection with relevant siRNAs. Cells were
counted at days 2, 4 and 6 after plating using a Countess II
cell counter. Proliferation curves and standard deviations
were generated using the PRISM 7 (GraphPad Software, La
Jolla, CA, USA) statistical tool.
For clonogenic assay, cells were seeded at 5 9 103 in
2 mL of complete medium in three biological replicates,
24 h after transfection with relevant siRNAs. Cells were
stained in crystal violet staining solution [0.5% (w/v) crys-
tal violet powder, 20% (v/v) ethanol] after 6 days and
plates were imaged using a ChemiDoc (BIORAD).
Transient knockdown by RNA interference
MCF7, MCF10A and MDA-MB-231 cells were plated in a
6-well tissue culture dish in the relevant culture media with-
out antibiotics for 24 h reaching 60–80% confluency. Cells
were then transfected with 100 nM final concentration
siRNA using Dharmafect I reagent following the manufac-
turer’s (Dharmacon, Lafayette, CO, USA) instructions. The
following ON-TARGET plus human siRNAs from Dharma-
con were used: hDDX3X siRNA#6: J-006874-06; hDDX3X
siRNA#8: J-006874-08; hKLF4 siRNA: J-005089-08; Non-
targeting siRNA (scrambled sequence): D-001810-01. Cells
were harvested 72 h after transfection and RNA and/or pro-
teins were extracted for downstream assays.
Generation of stable knockdown cell lines
through shRNA lentiviral transduction
Stable DDX3X knockdown MCF7 cells were obtained by
transduction of lentiviral particles bearing pLKO.1 plas-
mids expressing the relevant shRNA and the puromycin
selection cassette (hDDX3X shRNA: TRCN0000000001;
pLKO.1-puro NonMammalian shRNA Control Plasmid
DNA: SHC002).
MCF7 cells were plated in normal DMEM in 10 cm plate
to reach 70% confluency the next day. The viral suspension
(~6 mL) was supplemented with 8 lgmL1 human poly-
brene (Millipore, Burlington, MA, USA) and added to
MCF7 target cells. Cells were left at 37 °C, 5% (v/v) CO2
overnight. Cells were selected in puromycin-containing
media and used for CLIP–qPCR assays 72 h after selection.
Transient overexpression of human KLF4
MCF7 cells were plated in a 6-well tissue culture dish in the
relevant culture media without antibiotics for 24 h reaching
60–80% confluency. FuGENE transfection reagents were
used following manufacturer’s instructions (Promega, Madi-
son, WI, USA). Increasing amounts (0 lg, 0.5 lg, 1 lg, 2 lg)
of a pPB-CAG-hKLF4-pA-pgk-Hygro plasmid, combined
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with decreasing amounts of pGG131 control plasmid (to hold
the total amount of DNA at 2 lg in all conditions) were
transfected. Cells were harvested 48 h after transfection for
RNA extraction or processed for cells cycle analysis.
Cell cycle assessment
MCF7 cells transfected with either scrambled siRNA or
DDX3X targeting siRNA (#6 or #8). After 72 h they were
then treated with 50 ngmL1 nocodazole for a further 16 h
(overnight). Cells were detached by trypsinization, washed in
1X PBS containing 10 mM EDTA and pelleted by centrifuga-
tion at 120 g for 2 min. Pellets were resuspended in 100 lL
1X PBS containing 10 mM EDTA and 1% (w/v) BSA.
200 lL of propidium iodide (PI) staining solution [1% (v/v)
NP-40, PI 20 lgmL1, RNaseA 0.1 mgmL1 in 1X PBS,
10 mM EDTA, 1% (w/v) BSA] were added to resuspended
pellets. Samples were kept on ice and measured using a
FACSCalibur Cytometer (BD). At least 25 000 events per
sample were collected. Data were processed with FLOWJO soft-
ware. Standard deviation (error bars) and P-values were cal-
culated using the PRISM 7 statistical tool.
Quantitative real-time PCR for gene expression
quantification
Total RNA was purified from cells using a miRNeasy Mini
Kit (Qiagen, Hilden, Germany) following the manufac-
turer’s instructions. Excess contaminating DNA was
removed by on-column DNase digestion using the RNase-
Free DNase Set (Qiagen), following the manufacturer’s
instructions.
First strand cDNA synthesis was performed using Super-
script III Reverse Transcriptase kit (Invitrogen) according
to the manufacturer’s instructions.
Quantitative real-time PCR was performed using an ABI
StepOnePlus (Applied Biosystems, Foster City, CA, USA)
sequence detection system using SYBRgreen. PCR ampli-
fication was performed with an initial step of 10 min at
95 °C, followed by 40 cycles of 15 s at 95 °C and 1 min at
60 °C. Relative quantification was obtained calculating
ΔΔCt. GAPDH expression was used as reference gene.
Standard deviation (error bars) and P-values were calcu-
lated using the PRISM 7 statistical tool.
The following primers were used:
Chromatin immunoprecipitation and analysis of
the KLF4 gene
Two independent biological replicates were produced for each
condition. Briefly, 72 h after siRNA transfection, MCF7 cells
were cross-linked with 1% (v/v) formaldehyde for 15 min. at
room temperature and cross-linking was stopped by the addi-
tion of 0.125 M glycine. Cells were then lysed in 1% (w/v)
SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.0, 1 mM sodium
orthovanadate and protease inhibitors. Cells were sonicated
in a Bioruptor Pico (Diagenode, Seraing, Belgium) to achieve
a mean DNA fragment size of 500 bp. Immunoprecipitation
was performed with relevant antibodies [5 lg anti-RNA poly-
merase II antibody, clone CTD4H8 (Millipore, 05-623) and
control 5 lg GFP-ChIP Grade (Abcam, Cambridge, UK,
ab290)] for a minimum of 12 h at 4 °C in modified RIPA buf-
fer [1% (v/v) Triton X-100, 0.1% (w/v) deoxycholate, 0.1%
(w/v) SDS, 90 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM
sodium orthovanadate and EDTA-free protease inhibitors].
An equal volume of protein A and G Dynabeads were used to
bind the antibody and associated chromatin for 2 h at 4 °C.
The beads were extensively washed prior to elution of the
antibody bound chromatin. Reverse cross-linking of DNA
was followed by RNAse and Proteinase-K treatment and
DNA was purified using the Chip DNA Clean and Concen-
trate kit (Zymo Research, Irvine, CA, USA). Immuno-preci-
pitated DNA was analysed on an ABI StepOnePlus real-time
PCR instrument, using power SYBRgreen PCR Mastermix
according to the manufacturer’s instructions. The chromatin
immunoprecipitation efficiency was calculated as percentage
of input normalized to the internal control for RNAPII occu-
pancy, represented by GAPDH house-keeping gene promoter
region. Standard deviation (error bars) was calculated using
the PRISM 7 statistical tool.
The following primers were used for ChIP analysis of
KLF4 (A-E) and GAPDH:
DDX3X fw: ACTATGCCTCCAAAGGGTGTCC rev: AGAGCCAACTCTTCCTACAGCC
CCNA2 fw: CATGGACCTTCACCAGACCT rev: GATTTAGTGTCTCTGGTGGGTTG
CDK2 fw: CATTCCTCTTCCCCTCATCA rev: GCCCCCTCTGTGTTAATAAGC
KLF4 fw: CCATCCTTCCTGCCCGATC rev: CGTCTTCCCCTCTTTGGCTT
CCNE1 fw: CAGATGAAGAAATGGCCAAAA rev: TTTGGGTAAACCCGGTCAT
GAPDH fw: TGCACCACCAACTGCTTAGC rev: GGCATGGACTGTGGTCATGAG
Amplicon A fw: TTACCCAGTGGACTTGC rev: AACCAATGACCCTCTCAACTA
Amplicon B fw: GGAAAGGGCTTCGAGATG rev: AGCACTGTGCAGCGTGAACTG
Amplicon C fw: GAGCGACGAGAGCGGACTCCT rev: CCGTACTCACCGCCATTGTC
Amplicon D fw: TCCCATCTTTCTCCACGTTC rev: CGGGGACTGGTGAAGACC
Amplicon E fw: CGGCTCTGTAACACCATAA rev: TAGCACCCAGCCTACATTAAC
GAPDH fw: GCGCACGTAGCTCAGGCC rev: GAGCAGAGAGCGAAGCGGG
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RNA-seq libraries preparation
Total RNA was extracted (as described above) from MCF7
cells transfected with either a scrambled siRNA or DDX3X
targeting siRNA (#6 or #8) and harvested 72 h after trans-
fection. Three independent biological replicates were pro-
duced for each condition.
Ribosomal RNA was depleted using a Ribo-Zero rRNA
removal kit (Human/Mouse/Rat) from Illumina(R), follow-
ing the manufacturer’s instructions. RNA-seq libraries were
produced using NEXTflex RNA-Seq kit from Bio Scien-
tific, following the manufacturer’s instructions. Before mul-
tiplexing, excess primer was removed with AMPure XP
beads (Beckman Coulter, Brea, CA, USA). Before and
after multiplexing, libraries were tested for both size and
quantity of DNA using a Qubit dsDNA HS assay kit
and a high sensitivity D1000 ScreenTape system following
the manufacturer’s instructions.
Bioinformatic analysis
For differential gene expression analysis in DDX3X knock-
down MCF7 cells, trimmed reads were mapped in paired
end mode to the h38 human genome using tophat [29] with
the following parameters (–no-coverage- search –max-multi-
hits 300 –report-secondary-alignments –read- mismatches 2
–library-type fr-firststrand). Multihits (reads mapping to
multi loci) were filtered, along with reads mapping with
quality score less than 20. Reads were counted across
gene models taken from the Ensembl v86 gtf gene model list
using the summarizeOverlaps function from the
GenomicAlignments package in R [30]. The strand of each
read was inverted prior to counting to account for the fact
that libraries represent the first strand of synthesised cDNA.
Read counts were converted into normalized fragments per
kilobase mapped (FPKM) values for quality control plots.
Differential expression analysis was conducted on the raw
count data using the DESeq2 package in R [31]. P values
were corrected for multiple testing using the Benjamini and
Hochberg FDR correction. Significantly changing genes
were identified based on a fold change greater than twofold
(up or down) and an adjusted P value less than 0.05. In addi-
tion, significant genes were filtered to remove genes where
both the control and mutant samples had an average FPKM
score less than 1.
Gene Ontology analysis was performed by using default
settings of DAVID tool [32].
Bioconductor DEXseq tool using default parameters [33]
was used to identify differential exon usage between condi-
tions, indicating differences in gene splicing between the
conditions. This analysis indicates differences in gene splic-
ing between conditions by including exons as terms in the
model and looking for genes whereby differences between
the exons accounts for a significant proportion of the varia-
tion between the conditions.
Protein purification, detection and analysis
Cells were lysed by the addition of 1X SDS loading buffer
[200 mM Tris-HCl pH6.8, 20% (v/v) b-mercaptoethanol,
2% (w/v) SDS, 0.1% (w/v) bromophenol blue, 40% (w/v)
glycerol]. The lysates were sonicated using a VibraCell
probe sonicator (Sonics) for 20 s at 22% amplitude. The
samples were denatured by boiling for 5 min. and anal-
ysed by SDS/PAGE and western blotting. The following
antibodies were used in the indicated concentrations for
western blot: anti-DDX3 mouse monoclonal [Abcam
ab196032 (1 : 1000)]; anti-b-tubulin rabbit polyclonal
[Abcam ab6046 (1 : 1000)]; anti-GAPDH rabbit poly-
clonal [Abcam ab9483 (1 : 1000)]; anti-KLF4 rabbit poly-
clonal [Abcam ab106629 (1 : 1000)].
CLIP (UV Cross-linking immunoprecipitation)-
qPCR
Cross-linking immunoprecipitation-qPCR was performed
by adapting a published protocol for transcriptome-wide
iCLIP [34]. MCF7 cells were cultured in 10-cm diameter
dishes. When cells reached confluence, media was
removed, and cells were washed twice with ice-cold 1X
PBS. Ice -old 1X PBS was added, plates were placed on
ice and irradiated once at 150 mJcm2 at 254 nm. Cells
were scraped and harvested into Eppendorf tubes and cen-
trifuged at 15 800 g for 10 s at 4 °C. Cell pellets were
resuspended in CLIP lysis buffer [50 mM Tris-HCl, pH
7.4, 100 mM NaCl, 1% (v/v) Igepal CA-630, 0.1% (w/v)
SDS, 0.5% (w/v) sodium deoxycholate] supplemented with
protease inhibitor cocktail (CompleteTM, Roche, Basel,
Switzerland) and sonicated once using a VibraCell probe
sonicator (Sonics, Newtown, CT, USA) for 20 s at 22%
amplitude. Lysates were treated with 2 lL of Turbo
DNase (Life Technologies, Carlsbad, CA, USA) for
3 min. at 37 °C with shaking at 1,100 rpm and then
immediately placed on ice. Samples were then centrifuged
for 10 min at 22 000 g at 4 °C to clear the lysate. The
supernatant was collected and quantified using a bicin-
choninic acid assay (BCA). Protein G Dynabeads were
previously washed twice in lysis buffer and then resus-
pended in 100 lL lysis buffer with the relevant antibody
(3 lg anti-DDX3 mouse monoclonal-Abcam-ab196032;
3 lg mouse IgG2a Isotype Control Abcam-ab18413) and
incubated in rotation at room temperature for 1 h for
antibody absorption. The lysates were added to the anti-
body/beads mix and incubated overnight with rotation at
4 °C. The next day beads were washed four times in high
salt buffer [50 mM Tris-HCl, pH 7.4, 1 M NaCl, 1 mM
EDTA 1% (v/v) Igepal CA-630, 0.1% (w/v) SDS, 0.5%
(w/v) sodium deoxycholate] and twice in PK buffer
(100 mM Tris- HCl pH 7.4; 50 mM NaCl; 10 mM EDTA).
To digest the protein covalently bound to the RNAs and
release peptide-–RNA complexes, beads were resuspended
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Fig. 1. The DDX3X is required for breast cancer cells proliferation. (A) Western blot showing the protein levels of DDX3X and GAPDH in
MCF7 cells transfected with either scrambled siRNA or one of two different siRNAs targeting DDX3X (#6 or #8). Cells were harvested at
the indicated time points. Re-expression of DDX3X at day 4 is presumably due to loss of the transfected siRNAs. (B) Proliferation curves for
MCF7 cells treated as in A. Equal numbers of cells (3 9 104) were seeded for proliferation assays 24 h after transfection (day 0) and then
counted at the indicated time points. (C) Clonogenic assay of MCF7 cells treated as in A: 24 h after transfection, cells were seeded for
clonogenic growth and stained 6 days after seeding. Images from a representative experiment are shown. (D) Quantification of number of
colonies from C. P-values represent statistical significance calculated with unpaired t test comparing to scrambled siRNA condition
(P-values: ns. >0.05; *≤0.05; **≤0.01; ***≤0.001).
Fig. 2. Gene expression changes upon knockdown of DDX3X in MCF7 cells. (A) Volcano plots for each individual differential expression
analysis showing gene expression changes in MCF7 cells depleted of DDX3X with either DDX3X targeting siRNAs #6 or DDX3X targeting
siRNAs #8. Significant genes (based on the specified threshold values) are indicated by red (up-regulated) and blue (down-regulated) points.
Genes that are not changing in expression are coloured grey. (B) Correlation plot between the log-fold change for comparison of the two
siRNAs used to knockdown DDX3X (#6 and #8). (Red = genes up-regulated in both conditions; Blue = genes down-regulated in both
conditions; Green = genes significant in one condition or the other; Black = not significant genes.) The corresponding Pearson correlation
(‘Cor’) and P-value for a linear model (‘P val’) are shown. (C) GO term analysis of down-regulated genes upon knockdown of DDX3X in
MCF7 cells. Down-regulated genes in knockdown DDX3X MCF7 cells were identified from RNA-seq data as described in Materials and
methods. The GO enrichment of down-regulated genes was obtained using the DAVID functional annotation tool with default settings. The
P-values were calculated using the ‘default’ method of DAVID (P-Value ≤0.01). Y-axis shows the GO terms related to biological processes in
DDX3X knockdown MCF7 cells; X-axis shows –log10 P-values of each GO term. (D-E) Validation of RNA-seq upon DDX3X knockdown in
MCF7 cells. (D) Table showing selected genes for RT-qPCR validation: those transcripts resulted down-regulated (DDX3X, CCNA2, CDK2),
up-regulated (KLF4) or unchanged (CCNE1) in RNA-seq analysis of DDX3X knockdown MCF7 cells. (E) Levels of transcripts (listed in Table,
panel D) in MCF7 cells transfected with either scrambled siRNA or one of two different siRNAs targeting DDX3X (#6 or #8), measured by
RT-qPCR. Cells were harvested 72 h after transfection. Results represent the average of three replicates. P-values represent statistical
significance calculated with unpaired t test comparing to scrambled siRNA condition (P-values: ns. > 0.05; *≤0.05; **≤0.01; ***≤0.001;
****≤0.0001).
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in 50 lL PK buffer and 5 lL proteinase K (Roche,
03115828001) and incubated in shaking at 1,100 rpm for
30 min at 37 °C. RNA was extracted from the peptide–
RNA complexes using a miRNeasy Mini Kit (Qiagen)
following the manufacturer’s instructions. Excess contami-
nating DNA was removed by on-column DNase digestion
using the RNase-Free DNase Set (Qiagen), following
the manufacturer’s instructions. First strand cDNA
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synthesis was performed using Superscript III Reverse
Transcriptase kit (Invitrogen) according to the manufac-
turer’s instructions.
The following primers were used for detection of PUS1
mRNA negative control: fw: TGGTGAGGACATGAG
GAAAATG; rev: GAATGTGAGAGGGAAGGTGG.
A B
C
Fig. 3. DDX3X knockdown arrests MCF7 cells in G1 phase. MCF7 cell cycle progression flow cytometric analysis based on PI staining in
MCF7 cells 72 h after transfection with either scrambled siRNA or one of two different siRNAs targeting DDX3X (#6 or #8). (A) Western
blots showing protein levels of DDX3X and GAPDH in MCF7 cells transfected with scrambled siRNA or one of two different siRNAs
targeting DDX3X (#6 or #8). (B) Representative images from FlowJo analysis of flow cytometric analysis of cell cycle progression upon PI
staining (quantified in C). (C) Quantification of the data in B for each phase (G1-S-G2M) plotted as the difference in percentages for each
DDX3X siRNA used to those of the scrambled siRNA values. Results represent the average of two replicates. P-values represent statistical
significance calculated with unpaired t test comparing to scrambled siRNA condition (P-values: ns. >0.05; **≤0.01).
Fig. 4. Kruppel-like factor 4 mediates DDX3X-dependent regulation of cell cycle. (A) Western blot showing the protein levels of DDX3X,
KLF4 and b-tubulin in MCF7 cells transfected with either scrambled siRNA or one of two different siRNAs targeting DDX3X (#6 or #8). (B)
mRNA levels of DDX3X, CCNE1, KLF4, CCNA2 and CDK2 in MCF7 cells transfected with either scrambled siRNA or KLF4 targeting siRNA,
measured by qPCR. Cells were harvested 72 h after transfection. Results represent the average of three replicates. (C) mRNA levels of
DDX3X, CCNE1, KLF4, CCNA2 and CDK2 in MCF7 cells transfected with increasing amounts of a hKLF4 expressing plasmid (as described
in Materials and methods), measured by RT-qPCR. Cells were harvested 48 h after transfection. Results represent the average of three
replicates. (D) Cell cycle progression flow cytometric analysis in MCF7 cells transfected with increasing amount of a hKLF4 expressing
plasmid (as in C). Shown is the difference in percentages for each phase (G1–S–G2M) plotted as the difference in percentages for each
condition (0.5 lg hKLF4, 1 lg hKLF4, 2 lg hKLF4) to those of the 0 lg hKLF4 control values. Cells were harvested 48 h after transfection.
Results represent the average of two replicates. P-values represent statistical significance calculated with unpaired t test comparing to
scrambled siRNA or 0 lg conditions (P-values: ns. >0.05; **≤0.01; ***≤0.001). (E) Double knockdown of DDX3X and KLF4 in MCF7 cells:
levels of DDX3X, KLF4, CDK2 and CCNA2 transcripts in MCF7 cells transfected with either scrambled siRNA or #6 DDX3X siRNA or #8
DDX3X siRNA alone or combined with KLF4 targeting siRNA, measured by RT-qPCR. Cells were harvested 72 h after transfection. Results
represent the average of two replicates. P-values represent statistical significance calculated with unpaired t test comparing the double
transfection conditions to the single transfection respective condition (P-values: ns. >0.05; *≤0.05; **≤0.01; ***≤0.001; ****≤0.0001).
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RNA enrichment was quantified as percentage of Input.
Standard deviations (error bars) and P-values were calcu-
lated using the PRISM 7 statistical tool.
Results
DDX3X is required for proliferation of breast
cancer cells
In order to gain insight into the biological role of
DDX3X and investigate the specific requirement of
DDX3X function in breast cancer cells, we first anal-
ysed the proliferation rates of MCF7 breast epithelial
cancer cells upon knockdown of DDX3X.
MCF7 cells showed high sensitivity to DDX3X
knockdown using two independent siRNAs (Fig. 1A,
B). Seventy two hours after transfection with siRNA
(i.e. day 2 after seeding – see Material and Methods),
when depletion of DDX3X was virtually complete
(Fig. 1A), DDX3X-depleted MCF7 cells showed signifi-
cantly impaired growth compared to control cells trans-
fected with scrambled siRNA (Fig. 1B). In contrast,
DDX3X depletion in nontumourigenic breast epithelial
cells (MCF10A) showed little effect (Fig. S1).
We next performed a clonogenic assay in MCF7
cells upon knockdown of DDX3X using the same siR-
NAs. As shown, depletion of DDX3X significantly
reduced the number of colonies formed (Fig. 1C,D).
DDX3X regulates cell cycle in MCF7 cells
The importance of DDX3X in the proliferation of
MCF7 breast cancer cells suggested a relevant and
specific biological role for DDX3X in the growth of
this cell line. To examine which pathways might be
linked to reduced proliferation observed upon deple-
tion of DDX3X, we performed RNA-seq analysis of
MCF7 cells following knockdown of DDX3X with
each siRNA (#6 and #8) and compared the results to
those obtained from RNA-seq of control scrambled
siRNA cells. These analyses revealed that knockdown
of DDX3X caused significant gene expression changes
(Fig. 2A; Supporting Information SF2) with good
reproducibility between the two knockdown siRNAs
used (Pearson = 0.81) (Fig. 2B). A gene ontology
search using DAVID functional annotation tool was
used to categorize the differentially expressed genes.
Figure 2C shows the GO terms related to biological
processes for genes down-regulated upon DDX3X
knockdown in MCF7 cells. This analysis indicated that
genes encoding proteins involved in cell cycle were
down-regulated upon knockdown of DDX3X in
MCF7 cells.
We next validated, by qPCR, a subset of cell cycle
relevant genes whose expression was altered upon
DDX3X knockdown in MCF7 cells. As shown in
Fig. 2D,E, expression of these genes was altered
exactly as predicted from the RNA-seq data: CCNA2
and CDK2 expression was reduced upon DDX3X
knockdown, whilst CCNE1 expression was unchanged
and KLF4 expression was increased.
Given that the results from the RNA-seq analysis
highlighted altered expression of cell cycle related
genes in DDX3X-deficient cells, we next analysed cell
cycle progression of MCF7 cells upon DDX3X knock-
down. In agreement with our RNA-seq analysis,
knockdown of DDX3X in MCF7 cells caused a dra-
matic accumulation of cells in G1 phase, indicating an
Fig. 5. DDX3X binds KLF4 mRNA and regulates its splicing. (A) Chromatin immunoprecipitation (ChIP)–qPCR analysis of RNA polymerase II
(RNAPII) at the KLF4 gene in control (black bars) and DDX3X knockdown (red and blue bars) cells. ‘Normalized RNAPII enrichment’ ChIP
efficiency calculated as a percentage of input normalized to the internal control for RNAPII occupancy, represented in this case by a GAPDH
house-keeping gene promoter region. A schematic representation of the KLF4 gene is shown (note: it is transcribed from right to left), and
H3K4me3 and H3K27ac levels (from ENCODE) are included for reference purposes. The position of the amplicons analysed (A–E) are
indicated. A western blot showing the levels of DDX3X in knockdown cells (#6 and #8 DDX3X siRNAs) is shown to the right. (B) CLIP-qPCR
was performed as described in Materials and methods with anti-DDX3X and anti-IgG antibodies in MCF7 cells transduced with either
scrambled shRNA or DDX3X shRNA. RNA obtained from each immunoprecipitation was analysed by RT-qPCR to determine enrichment of
KLF4 mRNA. Results represent the average of three replicates. P-values represent statistical significance calculated with unpaired t test
comparing to scrambled shRNA condition (P-values: ns. > 0.05; *≤0.05; **≤0.01; ***≤0.001). (C) Western blot showing the protein levels of
DDX3X and b-tubulin in MCF7 cells used in B. (D) Differential exon usage analysis in KLF4 mRNA upon DDX3X knockdown. Gene model
colour code from purple to white indicates the descending statistical significance of the difference observed for each exon usage (purple: P-
value ≤5.0E-4; grey box: P-value >5.0E-4; white box: N.A.). Analysis was obtained using DEXseq (Cut-off P-value ≤5.0E-4); Top
panel = normalized counts average of replicates for each sample; bottom panel = flattened gene model highlighting alternative annotated
transcripts. (Red) Data from #6 DDX3X siRNA knockdown samples; (Blue) scrambled control. For each significant gene, all of the exons
across all isoforms are labelled (E001, E002, etc.) and the ‘exon usage’ (essentially a normalized read count at that exon) is plotted for each
of the conditions (averaged between the replicates). An exon (E001) that shows a significant difference between the conditions is
highlighted in purple (P-value ≤5.0E-4).
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impairment of cell cycle progression to DNA replica-
tion (Fig. 3A–C).
Taken together, these data indicate that DDX3X
exerts regulatory activity on the cell cycle of MCF7
cells, and that its loss impairs progression of cells into
S phase.
KLF4 mediates DDX3X-dependent regulation of
MCF7 cell cycle
Transcriptome and cell cycle analysis upon depletion
of DDX3X highlighted the role of this helicase in cel-
lular proliferation and cell cycle progression in MCF7
breast cancer cells. Interestingly, whilst cell cycle effec-
tor genes, such as cyclins and cyclin-dependent
kinases, were down-regulated upon knockdown of
DDX3X, expression of the negative regulator of the
cell cycle, KLF4 [35], was dramatically increased in
MCF7 cells (Fig. 2E) as well as in more aggressive
MDA-MB-231 breast cancer cells (Fig. S3). We there-
fore considered whether increased expression of KLF4
could mediate the growth and cell cycle effects
observed upon knockdown of DDX3X.
We confirmed that DDX3X knockdown enhances
expression of KLF4 not only at the mRNA level
(Fig. 2E) but also at the protein level in MCF7 cells
(Fig. 4A). In fact, the KLF4 transcription factor was
relatively weakly expressed in control MCF7 cells
(transfected with scrambled siRNA), but it was
robustly induced upon DDX3X knockdown. In line
with these results, we reasoned that DDX3X modu-
lates the cell cycle of MCF7 cells, at least in part, by
maintaining relatively low levels of KLF4 which in
turn allows expression of cell cycle effector proteins to
promote cell cycle progression. To test this hypothesis,
we decided to focus on the link between KLF4 up-reg-
ulation and the down-regulation of cyclins and cyclin-
dependent kinases detected upon DDX3X knockdown,
which would ultimately result in the observed G1
arrest (Figs 2E and 3).
If the phenotype observed upon DDX3X knockdown
is due to up-regulation of KLF4, then depletion of
KLF4 should increase expression of CCNA2 and CDK2.
Conversely, overexpression of KLF4 should phenocopy
the effects caused by knocking down DDX3X. As shown
in Fig. 4B, knockdown of KLF4 in MCF7 cells
enhanced expression of CCNA2 and CDK2. In contrast,
CCNE1 gene expression, which was unchanged when
DDX3X was depleted, also remained unchanged upon
KLF4 knockdown. Importantly, DDX3X levels did not
change upon KLF4 knockdown. Moreover, KLF4 over-
expression affected the expression of these genes in a
similar manner to that observed upon DDX3X
knockdown (Figs 2E and 4C). Indeed, the expression of
genes that were down-regulated upon DDX3X knock-
down (CCNA2, CDK2) was decreased proportionally to
the level of KLF4 overexpression. CCNE1 gene expres-
sion, which was unchanged in DDX3X knockdown, also
showed no change upon KLF4 overexpression (Fig. 4C).
These results are entirely consistent with the notion that
the effects observed upon DDX3X knockdown are lar-
gely due to elevated expression of KLF4 in MCF7 breast
cancer cells.
We then investigated whether overexpression of
KLF4 would phenocopy the effect of DDX3X deple-
tion on cell cycle progression of MCF7 cells. As
expected, overexpression of KLF4 caused accumula-
tion of cells arrested in G1 phase (Fig. 4D), similar to
that observed upon DDX3X knockdown (Fig. 3).
Finally, we examined whether depletion of both
DDX3X and KLF4 would rescue the down-regulation
of CDK2 and CCNA2 cell cycle genes, observed upon
knockdown of DDX3X alone. Importantly, depletion
of both DDX3X and KLF4 in MCF7 cells partially
restored the expression of both CDK2 and CCNA2
genes (Fig. 4E).
Overall, these findings show that up-regulation of
KLF4, induced by depletion of DDX3X expression in
MCF7 cells, very likely drives the cell cycle arrest
observed upon DDX3X knockdown. Furthermore, our
data indicate that DDX3X’s cell cycle regulatory activ-
ity may function directly through the DDX3X-depen-
dent inhibition of KLF4 transcription factor expression.
Since the level of KLF4 mRNA and protein are
affected by DDX3X expression (Figs 2E and 4A), we
first tested whether knockdown of DDX3X induces
KLF4 expression at the level of transcription. To do
so, we used an anti-RNA polymerase II antibody in
chromatin immunoprecipitation experiments and
examined polymerase occupancy at the KLF4 gene in
control and DDX3X knockdown cells (Fig. 5A). We
observed no effect of depleting DDX3X at any of the
amplicons analysed (Fig. 5A). These results indicate
that DDX3X depletion does not induce expression of
KLF4 by increasing its rate of transcription.
Next, we reasoned that the helicase could regulate
KLF4 function post-transcriptionally by directly bind-
ing to its mRNA. We therefore performed UV cross-
linking immunoprecipitation (CLIP) to test for direct
interaction between DDX3X protein and KLF4 mRNA.
As shown (Fig. 5B,C), KLF4 mRNA was specifically
enriched in DDX3X immunoprecipitates in MCF7 cells
expressing normal levels of DDX3X. Importantly, bind-
ing of DDX3X to KLF4 mRNA was lost when DDX3X
was knocked-down (Fig. 5B,C), testifying to the speci-
ficity of the assay. Moreover, specificity was further
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confirmed by showing that another helicase protein,
DDX24, does not bind to KLF4 mRNA, whilst neither
DDX3X nor DDX24 bound to a control mRNA, PUS1
mRNA (Fig. S4). Thus, DDX3X directly interacts with
KLF4 transcripts.
Given this, we next tested the hypothesis that
DDX3X regulates KLF4 mRNA splicing by analysing
the effect of DDX3X depletion upon exon usage in
KLF4 mRNA. This identified significant differences in
the usage of a number of exons, particularly in the
inclusion of exon 1 (Fig. 5D). These observations sug-
gest that DDX3X regulates the selection of certain
exons during KLF4 mRNA splicing, thereby regulating
production of specific KLF4 isoforms.
Taken together, our findings reveal a robust nega-
tive effect of DDX3X on the expression of KLF4
mRNA and protein and they suggest that DDX3X’s
biological function in MCF7 breast cancer cells is
linked to its direct binding to KLF4 transcripts.
Discussion
In the present work, we show that DDX3X is required
for efficient proliferation of MCF7 breast cancer cells
and for their progression through the cell cycle, specifi-
cally into S phase. This confirms similar findings from
other groups [26,27]. Moreover, a similar role for
DDX3X in regulating the cell cycle was previously
reported in lung cancer cells and colorectal cancer cells
in which depletion of DDX3X significantly reduced
proliferation and caused a G1 arrest [22,23]. In a sepa-
rate study, DDX3X regulation of CCNE1 mRNA
translation was responsible for progression of HeLa
cells to S phase [36]. In this cell line, DDX3X was
required for production of CCNE1 protein but not for
CCNE1 mRNA levels. Consistent with this, our data
show that the mRNA level of CCNE1 is not affected
by DDX3X knockdown in MCF7 cells. Instead,
expression of positive cell cycle regulators CCNA2 and
CDK2 was reduced and expression of a negative mas-
ter regulator of the cell cycle, KLF4, was significantly
increased in DDX3X-depleted MCF7 cells. Moreover,
we show that DDX3X directly interacts with KLF4
mRNA and that KLF4 protein levels are strongly
increased upon DDX3X knockdown. Indeed, we pro-
vide evidence that DDX3X regulates KLF4 mRNA
alternative splicing in a way that would likely affect its
protein production. Although our ChIP experiments
indicate that DDX3X depletion does not affect KLF4
gene transcription, it remains a possibility that
DDX3X regulates KLF4 splicing in a cotranscriptional
manner.
We propose a model in which DDX3X exerts onco-
genic activity by binding to KLF4 mRNA to inhibit its
correct splicing thereby promoting expression of key
cell cycle genes (e.g. CCNA2 and CDK2) (Fig. 6).
Based on our observations, we speculate that binding
of DDX3X, which leads to an altered splicing pattern
Normal [DDX3X]
DDX3X
      Promotes mRNA
degradation or turnover?
Inhibits translation?KLF4 mRNA
AAAA
- Low KLF4 protein
- normal CDK2 and
   CCNA2 proteins
 Cell cycle
progression
AAAA
KLF4 protein
ribosome
- Increased KLF4 protein
- Inhibition of CDK2 and
CCNA2 transcription
Cell cycle arrest in G1
Low [DDX3X]
AAAA
KLF4 protein
ribosome
Increased KLF4 mRNA
negative splicing regulation
Fig. 6. Model of DDX3X-dependent regulation of cell cycle through repression of KLF4 expression.
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of KLF4 mRNA, produces an unstable RNA isoform
that is then targeted for degradation. Alternatively,
but not necessarily mutually exclusively, DDX3X may
directly inhibit translation of KLF4 mRNA. This
would be consistent with the reported ability of
DDX3X to interact with members of the translational
machinery [37–40].
In our model, we propose that the cell cycle regula-
tory activity of DDX3X is exerted through its regulation
of KLF4 mRNA and protein levels. In agreement with
this, we observed that knockdown of KLF4 induced
expression of CCNA2 and CDK2 genes that were down-
regulated by DDX3X knockdown. When KLF4 was
overexpressed in MCF7 cells, expression of CCNA2 and
CDK2 was reduced proportionally to the level of expres-
sion of KLF4 and consistent with the observed increased
cell cycle arrest in G1. Moreover, when both DDX3X
and KLF4 were depleted, the levels of CDK2 and
CCNA2 expression were partially restored compared to
the down-regulation observed upon knockdown of
DDX3X alone. However, the higher CDK2 and CCNA2
expression levels detected with KLF4 siRNA alone com-
pared with DDX3X and KLF4 siRNAs together, sug-
gests that DDX3X might also regulate expression of
CDK2 and CCNA2 mRNAs through additional mecha-
nisms, independently of KLF4.
Association between Cyclin A2 (encoded by CCNA2)
and CDK2 is necessary for cell cycle progression into S
phase and it is specifically required for DNA replication
[41–44]. Interestingly, among the genes down-regulated
upon DDX3X knockdown in MCF7 cells, many genes
encode replication-related factors such as the replication
origin recognition complex 1 (ORC1), factors involved
in DNA replication regulation (CDC6 and CDC45)
and chromosome-related factors such as minichromo-
some maintenance proteins (MCM2, 3, 5, 7, 8,10) that
associate with chromatin in G1 (Fig. S2). This suggests
DDX3X may have a broad role in regulating S phase-
relevant factors.
DEAD box proteins have been suggested to exert
both oncogenic and tumour-suppressive roles, in a
context- and cancer-dependent fashion and through
different mechanisms that affect a wide range of
molecular events, from transcription to translation
[13,19]. These observations have highlighted DDX
enzymes as potential candidates for therapeutic devel-
opment as well as disease biomarkers [13]. Inhibitors
of NTPase activity (like nucleoside analogues),
which affect RNA binding and helicase activity of
DEAD-box proteins, have already been designed,
tested and shown to possess anticancer potential [45].
Our findings that up-regulation of KLF4 mRNA upon
DDX3X knockdown in both MCF7 cells and MDA-
MB 231 cells suggests that the DDX3X:KLF4 axis of
cell cycle regulation could be a common feature of
breast cancer cell lines. Furthermore, the fact that
DDX3X possesses a proproliferative function in
breast cancer cells but not in nontumourigenic breast
epithelial cells [26], highlights this RNA helicase as a
potential therapeutic target in the fight against breast
cancer.
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